Christine M Metz

US Patent:

7741057, Jun 22, 2010

Filed:

Oct 31, 2007

Appl. No.:

11/931442

Inventors:

Richard J. Bucala - Cos Cob CT, US
Lin Leng - New York NY, US
Christine N. Metz - Great Neck NY, US

Assignee:

Cytokine PharmaSciences, Inc. - King of Prussia PA

International Classification:

G01N 33/53
C07K 14/52
C07K 14/715

US Classification:

435 71, 435 4, 435 72, 530350

Abstract:

Methods and compositions for using the MHC class II invariant chain polypeptide, Ii (also known as CD74), as a receptor for macrophage migration inhibitory factor (MIF), are disclosed. These include methods and compositions for using this receptor, as well as agonists and antagonists of MIF which bind to this receptor, or which otherwise modulate the interaction of MIF with CD74 or the consequences of such interaction, in treatment of conditions characterized by locally or systemically altered MIF levels, particularly inflammatory conditions and cancer.

US Patent:

8391970, Mar 5, 2013

Filed:

Aug 26, 2008

Appl. No.:

12/198808

Inventors:

Kevin J. Tracey - Old Greenwich CT, US
Howland Shaw Warren - Cambridge MA, US
Christine N. Metz - Great Neck NY, US

Assignee:

The Feinstein Institute for Medical Research - Manhasset NY

International Classification:

A61N 1/00

US Classification:

607 2, 607 62

Abstract:

Described herein are methods, devices and systems for inhibition of granulocyte activation by appropriate stimulation of the vagus nerve. Methods of treating granulocyte-mediated disorders (including inflammatory disorders) by stimulating the vagus nerve to inhibit granulocyte activation (particularly neutrophil activation) are also described. Appropriate stimulation may be very low levels of stimulation, including stimulation that does not result in desensitization. The level of granulocyte activation may be detected and used to at least partially control stimulation.

US Patent:

8617822, Dec 31, 2013

Filed:

May 17, 2010

Appl. No.:

12/781546

Inventors:

Richard J. Bucala - Cos Cob CT, US
Lin Leng - New York NY, US
Christine N. Metz - Great Neck NY, US

Assignee:

Baxter International Inc. - Deerfield IL
Baxter Healthcare SA - Glattpark (Opfikon)

International Classification:

G01N 33/53
C07K 14/52
C07K 14/715

US Classification:

435 71

Abstract:

Methods and compositions for using the MHC class II invariant chain polypeptide, Ii (also known as CD74), as a receptor for macrophage migration inhibitory factor (MIF), are disclosed. These include methods and compositions for using this receptor, as well as agonists and antagonists of MIF which bind to this receptor, or which otherwise modulate the interaction of MIF with CD74 or the consequences of such interaction, in treatment of conditions characterized by locally or systemically altered MIF levels, particularly inflammatory conditions and cancer.

US Patent:

20020114812, Aug 22, 2002

Filed:

Jan 14, 2002

Appl. No.:

10/043322

Inventors:

Riichiro Abe - Kita-Ku, JP
Richard Bucala - Cos Cob CT, US
Christine Metz - Great Neck NY, US

International Classification:

A61K039/395
A61K048/00

US Classification:

424/155100, 514/044000, 424/093210

Abstract:

Regulation of expression of CTL activity by macrophage migration inhibitory factor (MIF) is disclosed. In a mouse model using the EL4 tumor, cultured splenocytes from tumor-primed mice secrete high levels of MIF following antigen stimulation in vitro. Parallel splenocytes treated with neutralizing anti-MIF mAb showed a significant increase in CTL response against tumor cells compared to control mAb-treated cultures, with elevated expression of IFN. Histology of tumors from anti-MIF treated animals showed increases in infiltration of both CD4 and CD8 T cells, as well as apoptotic tumor cells, consistent with observed augmentation of CTL activity in vivo by anti-MIF, which was associated with enhanced expression of the common chain of the IL-2 receptor that mediates CD8T cell survival. CD8 cells of anti-MIF treated tumor-bearing mice showed increased migration into tumors of control mice. Methods for enhancing a CTL response by inhibition of MIF are disclosed.

US Patent:

20030003576, Jan 2, 2003

Filed:

Jun 4, 2002

Appl. No.:

10/160048

Inventors:

Riichiro Abe - Sapporo, JP
Richard Bucala - Cos Cob CT, US
Seamas Donnelly - Dublin, IE
Christine Metz - Great Neck NY, US

International Classification:

C12N005/08

US Classification:

435/372000

Abstract:

Disclosed are the identification of a differentiation pathway of cultured fibrocytes, characterization of the signals for fibrocyte migration to wound sites in vivo, and the potential role of fibrocytes in wound contracture. The invention relates to a method for producing fibrocytes comprising contacting a population of human peripheral blood mononuclear cells (PBMC) comprising predominantly CD14 cells with autologous T cells or a form of TGF, preferably TGF, thereby inducing differentiation of fibrocytes from precursors in the PBMC population. These fibrocytes are useful for treating a wound in a mammalian subject by administering fibrocytes to the subject, preferably in combination with TGF. Also disclosed are methods for attracting or targeting fibrocytes to a wound by administering SLC or another agonist of the CCR7 chemokine receptor, at or near the site of the wound, and methods of decreasing undesired wound fibrosis by inhibiting fibrocyte activity.

US Patent:

20030013122, Jan 16, 2003

Filed:

Mar 29, 2002

Appl. No.:

10/108383

Inventors:

Richard Bucala - Cos Cob CT, US
Lin Leng - New York NY, US
Christine Metz - Great Neck NY, US

International Classification:

A61K039/395
G01N033/53

US Classification:

435/007100, 530/388230, 424/145100

Abstract:

Methods and compositions for using the MHC class II invariant chain polypeptide, Ii (also known as CD74), as a receptor for macrophage migration inhibitory factor (MIF), are disclosed. These include methods and compositions for using this receptor, as well as agonists and antagonists of MIF which bind to this receptor, or which otherwise modulate the interaction of MIF with CD74 or the consequences of such interaction, in treatment of conditions characterized by locally or systemically altered MIF levels, particularly inflammatory conditions and cancer.

US Patent:

20060024754, Feb 2, 2006

Filed:

Sep 22, 2005

Appl. No.:

11/231990

Inventors:

Richard Bucala - Cos Cob CT, US
Lin Leng - New York NY, US
Christine Metz - Great Neck NY, US

International Classification:

G01N 33/53
C07K 16/28

US Classification:

435007100, 530388220

Abstract:

Methods and compositions for using the MHC class II invariant chain polypeptide, Ii (also known as CD74), as a receptor for macrophage migration inhibitory factor (MIF), are disclosed. These include methods and compositions for using this receptor, as well as agonists and antagonists of MIF which bind to this receptor, or which otherwise modulate the interaction of MIF with CD74 or the consequences of such interaction, in treatment of conditions characterized by locally or systemically altered MIF levels, particularly inflammatory conditions and cancer.

US Patent:

20090263404, Oct 22, 2009

Filed:

Apr 4, 2008

Appl. No.:

12/098220

Inventors:

Richard J. Bucala - Cos Cob CT, US
Lin Leng - New York NY, US
Christine N. Metz - Great Neck NY, US

International Classification:

A61K 39/395
C12N 5/00
G01N 33/68
C07K 16/00
A61P 37/00

US Classification:

4241731, 435375, 436 86, 5303873, 53038873, 5303896

Abstract:

Methods and compositions for using the MHC class II invariant chain polypeptide, Ii (also known as CD74), as a receptor for macrophage migration inhibitory factor (MIF), are disclosed. These include methods and compositions for using this receptor, as well as agonists and antagonists of MIF which bind to this receptor, or which otherwise modulate the interaction of MIF with CD74 or the consequences of such interaction, in treatment of conditions characterized by locally or systemically altered MIF levels, particularly inflammatory conditions and cancer.